378P Liquid biopsy detects early molecular response and predicts benefit to first-line chemotherapy plus cetuximab in metastatic colorectal cancer: PLATFORM-B study

Abstract

Chemotherapy plus anti-EGFR therapy is the standard first-line treatment in RAS wild-type (wt) metastatic colorectal cancer (mCRC). The utility of ctDNA sequencing (liquid biopsy) to assess early molecular response to chemotherapy plus anti-EGFR therapy before radiological progression is yet to be determined, and should integrate information on changes in total tumor burden and early emergence of resistant sub-clones.